AUGTYRO Market Summary

Key Factors Driving AUGTYRO Growth

1. Strong efficacy in ROS1-positive NSCLC supports first-line uptake

AUGTYRO's pivotal TRIDENT-1 study demonstrated substantial and durable activity in ROS1-positive advanced/metastatic NSCLC. In the TKI-naïve cohort, the objective response rate was 79% (56/71 patients), with a median duration of response of approximately 34 months at longer follow-up. These results support AUGTYRO as a clinically differentiated option in ROS1-positive NSCLC. The NCCN has subsequently listed repotrectinib as a preferred first-line treatment option for certain patients with ROS1-positive advanced/metastatic NSCLC.

2. CNS penetration is an important competitive advantage

CNS metastases are a major challenge in ROS1-positive NSCLC, and earlier-generation ROS1 TKIs have limitations in intracranial disease and resistance. Repotrectinib was specifically designed as a next-generation ROS1 inhibitor with CNS activity. TRIDENT-1 demonstrated intracranial responses in both TKI-naïve and previously treated patients, while peer-reviewed analyses have highlighted its activity against CNS disease. This can support physician preference for patients with brain metastases or a high risk of CNS progression.

3. Activity against ROS1 resistance mutations expands its use after prior TKI therapy

A key differentiator is AUGTYRO's activity against ROS1 G2032R, a clinically important resistance mutation that can emerge after treatment with earlier-generation ROS1 TKIs. FDA's November 2023 approval specifically included patients who had previously received a ROS1 TKI, making AUGTYRO the first FDA-approved ROS1 therapy with a label encompassing both TKI-naïve and TKI-pretreated patients. This creates a second-line treatment opportunity in addition to first-line use and can extend the duration of treatment across the ROS1 patient journey.

4. NTRK tumor-agnostic approval substantially broadens the addressable population

In June 2024, FDA granted accelerated approval for AUGTYRO in adults and pediatric patients ≥12 years with locally advanced/metastatic NTRK gene-fusion-positive solid tumors, or tumors where surgery would cause severe morbidity, following progression or when there is no satisfactory alternative therapy. This tumor-agnostic indication allows AUGTYRO to be used across multiple cancer types rather than being restricted to NSCLC.

Importantly, updated clinical data published in 2026 showed a 48% response rate among 69 NTRK-TKI-pretreated patients, with median duration of response of 9.8 months, providing additional evidence for activity in a difficult-to-treat population.

AUGTYRO Recent Developments

In January 2026, Zai Lab Limited announced that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO™ (repotrectinib) for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The approval is intended for patients whose disease is locally advanced or metastatic, or where surgical resection is likely to result in morbidity, and who have either progressed following prior therapies or have no satisfactory alternative treatment options.

“AUGTYRO Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of AUGTYRO for approved indication like Non-small cell lung cancer and Solid tumours; as well as potential indication like Adenocarcinoma, CNS cancer, Lymphoma, and Multiple myeloma in the 7MM. A detailed picture of AUGTYRO’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the AUGTYRO for approved and potential indications. The AUGTYRO market report provides insights about AUGTYRO’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current AUGTYRO performance, future market assessments inclusive of the AUGTYRO market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of AUGTYRO sales forecasts, along with factors driving its market.

AUGTYRO Drug Summary

AUGTYRO is a next-generation oral tyrosine kinase inhibitor (TKI) developed by Bristol Myers Squibb for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) and adults and pediatric patients aged 12 years and older with NTRK gene fusion-positive solid tumors that are locally advanced, metastatic, or for which surgical resection is likely to result in severe morbidity and that have progressed following treatment or have no satisfactory alternative therapy. Repotrectinib is designed to inhibit ROS1 and TRK family kinases (TRKA, TRKB, and TRKC), thereby blocking kinase-mediated signaling pathways that promote tumor-cell proliferation and survival; its activity also extends to certain resistance mutations that can emerge following earlier targeted therapies. AUGTYRO is administered orally, with a recommended dosage of 160 mg once daily for the first 14 days followed by 160 mg twice daily, continued until disease progression or unacceptable toxicity. The drug received U.S. FDA approval for ROS1-positive NSCLC in November 2023 and an accelerated approval for NTRK gene fusion-positive solid tumors in June 2024, expanding its use as a tissue-agnostic targeted therapy for tumors driven by NTRK fusions. The report provides AUGTYRO’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the AUGTYRO Market Report

The report provides insights into:

• A comprehensive product overview including the AUGTYRO MoA, description, dosage and administration, research and development activities in approved indications like Non-small cell lung cancer and Solid tumours; as well as potential indication like Adenocarcinoma, CNS cancer, Lymphoma, and Multiple myeloma.
• Elaborated details on AUGTYRO regulatory milestones and other development activities have been provided in AUGTYRO market report.
• The report also highlights AUGTYRO‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The AUGTYRO market report also covers the patents information, generic entry and impact on cost cut.
• The AUGTYRO market report contains current and forecasted AUGTYRO sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The AUGTYRO market report also features the SWOT analysis with analyst views for AUGTYRO in approved and potential indications.

Methodology

The AUGTYRO market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AUGTYRO Analytical Perspective by DelveInsight

• In-depth AUGTYRO Market Assessment

This AUGTYRO sales market forecast report provides a detailed market assessment of AUGTYRO for approved indication like Non-small cell lung cancer and Solid tumours; as well as potential indication like Adenocarcinoma, CNS cancer, Lymphoma, and Multiple myeloma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted AUGTYRO sales data uptil 2034.

• AUGTYRO Clinical Assessment

The AUGTYRO market report provides the clinical trials information of AUGTYRO for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

AUGTYRO Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

AUGTYRO Market Potential & Revenue Forecast

• Projected market size for the AUGTYRO and its key indications
• Estimated AUGTYRO sales potential (AUGTYRO peak sales forecasts)
• AUGTYRO Pricing strategies and reimbursement landscape

AUGTYRO Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• AUGTYRO Market positioning compared to existing treatments
• AUGTYRO Strengths & weaknesses relative to competitors

AUGTYRO Regulatory & Commercial Milestones

• AUGTYRO Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

AUGTYRO Clinical Differentiation

• AUGTYRO Efficacy & safety advantages over existing drugs
• AUGTYRO Unique selling points

AUGTYRO Market Report Highlights

• In the coming years, the AUGTYRO market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The AUGTYRO companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AUGTYRO’s dominance.
• Other emerging products for Non-small cell lung cancer and Solid tumours; as well as potential indication like Adenocarcinoma, CNS cancer, Lymphoma, and Multiple myeloma are expected to give tough market competition to AUGTYRO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AUGTYRO in approved and potential indications.
• Analyse AUGTYRO cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted AUGTYRO sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of AUGTYRO in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of AUGTYRO? How strong is AUGTYRO’s clinical and commercial performance?
• What is AUGTYRO’s clinical trial status in each individual indications such as Non-small cell lung cancer and Solid tumours; as well as potential indication like Adenocarcinoma, CNS cancer, Lymphoma, and Multiple myeloma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AUGTYRO Manufacturers?
• What are the key designations that have been granted to AUGTYRO for approved and potential indications? How are they going to impact AUGTYRO’s penetration in various geographies?
• What is the current and forecasted AUGTYRO market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of AUGTYRO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to AUGTYRO for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is AUGTYRO? What is the duration of therapy and what are the geographical variations in cost per patient?